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Background. We explored the establishment of abnormal blood-brain barrier (BBB) permeability and its relationship to neuro-
pathogenesis during primary human immunodeficiency virus (HIV) infection by evaluating the cerebrospinal fluid (CSF) to serum 
albumin quotient (QAlb) in patients with primary HIV infection. We also analyzed effects of initiating combination antiretroviral 
therapy (cART).
Methods. The QAlb was measured in longitudinal observational studies of primary HIV infection. We analyzed trajectories of 
the QAlb before and after cART initiation, using mixed-effects models, and associations between the QAlb and the CSF level of neuro-
filament light chain (NFL), the ratio of N-acetylaspartate to creatinine levels (a magnetic resonance spectroscopy neuronal integrity 
biomarker), and neuropsychological performance.
Results. The baseline age-adjusted QAlb was elevated in 106 patients with primary HIV infection (median time of measurement, 
91 days after infection), compared with that in 64 controls (P = .02). Before cART initiation, the QAlb increased over time in 84 par-
ticipants with a normal baseline QAlb (P = .006) and decreased in 22 with a high baseline QAlb (P = .011). The QAlb did not change after 
a median cART duration of 398 days, initiated at a median interval of 225 days after infection (P = .174). The QAlb correlated with 
the NFL level at baseline (r = 0.497 and P < .001) and longitudinally (r = 0.555 and P < .001) and with the ratio of N-acetylaspartate 
to creatinine levels in parietal gray matter (r = −0.352 and P < .001 at baseline and r = −0.387 and P = .008 longitudinally) but not 
with neuropsychological performance.
Conclusion. The QAlb rises during primary HIV infection, associates with neuronal injury, and does not significantly improve 
over a year of treatment. BBB-associated neuropathogenesis in HIV-infected patients may initiate during primary infection.
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Chronic exposure to human immunodeficiency virus (HIV) can 
lead to neurological complications, with one third of untreated 
individuals with advanced AIDS developing HIV-associated 
dementia [1, 2], a syndrome of severe cognitive, motor, and 
behavioral disturbances primarily associated with subcortical 
atrophy [3]. Although the incidence of HIV-associated demen-
tia has significantly decreased with the advent of combination 
antiretroviral therapy (cART), a milder spectrum of neurocog-
nitive deficits persists despite treatment [1, 2, 4]. As this per-
sisting impairment may at least in part represent irreversible 
alterations of central nervous system (CNS) integrity accrued 
before the initiation of cART, investigative efforts have been 
drawn toward elucidating neuropathogenesis during the early 
stages of HIV neuroinvasion and examining the effects of early 
cART on these processes.
Primary HIV infection (PHI) refers to the first phase of 
infection, from the time of transmission up to 12 months after 
transmission [5]. HIV infiltrates the CNS during PHI [6–8], 
as indicated by the presence of HIV RNA in the cerebrospinal 
fluid (CSF) compartment, even in the absence of neurological 
symptoms [1, 8–11]. CNS immune activation accompanies 
this viral invasion, as reflected by elevations in the CSF white 
blood cell count and the soluble CSF biomarkers neopterin 
(reflecting macrophage activation) and CXCL-10/IP-10 (a lym-
phocyte chemokine) and by T-lymphocyte activation in CSF 
[1, 12–15]. Furthermore, markers of immune activation may 
reflect the degree of viral load and neurocognitive impairment 
[16]. Magnetic resonance spectroscopy (MRS), a noninvasive 
quantitative MR technique that measures alterations in cerebral 
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metabolite levels, demonstrates that inflammatory cerebral 
metabolites are elevated in acute HIV infection (ie, the period 
before antibody seroconversion) and longitudinally increased 
over time in PHI before cART initiation [1, 17, 18]. Thus, cru-
cial processes during the primary phase of viral infection may 
underlie the initiation of HIV-associated CNS injury.
It is speculated that increased blood-brain barrier (BBB) per-
meability is a critical contributor to HIV neuropathogenesis 
because disruption of this regulatory interface facilitates CNS 
infiltration of potentially harmful substances from the periph-
ery, resulting in compounding viral entry and susceptibility to 
the inflammatory assault of immune cells [19, 20]. To exert its 
neurological effects, HIV-1 and/or its viral products must first 
traverse the BBB. Although data suggest that, at this initial 
stage, HIV is transported to the CNS via trafficking of infected 
immune cells across a largely intact BBB, increased permeability 
of the BBB has been implicated in the progression of HIV neu-
rological dysfunction [19, 21–24]. The ratio of the albumin level 
in the CSF to that in serum (also known as the CSF to serum 
albumin concentration quotient [QAlb]) is the best established 
fluid marker for BBB permeability [25]. Albumin is synthesized 
exclusively in the liver and is largely excluded from the CSF. 
Upon deregulation of the neurovascular unit and sequential 
loss of tight junctions, BBB permeability to albumin increases, 
resulting in an increased QAlb.
In this study, we aimed to elucidate the natural history of BBB 
permeability during PHI and to determine whether changes 
in permeability, if present, were associated with biomarkers 
of neuropathogenesis. Additionally, we sought to determine 
whether BBB permeability was responsive to cART initiated 
during PHI. These results provide novel understanding of the 
changes to the brain microenvironment that begin during ini-
tial HIV infection and the persistence of these alterations in the 
setting of early, virologically suppressive cART.
MATERIALS AND METHODS
Study Design
Individuals with PHI were recruited into prospective longi-
tudinal studies of CNS HIV in Gothenburg, Sweden, and San 
Francisco, California, between 1986 and 2014, as previously 
described [9]. Participants were enrolled within the first year 
after HIV transmission, as confirmed by the standard serologic 
testing algorithm for recent HIV seroconversion (STAHRS) 
[26], and all but 3 were ART naive. A  subset began cART at 
variable times during follow-up for reasons outside of the study. 
None of the participants had a prior neurological disease his-
tory. A history of substance abuse was not an exclusion crite-
rion, but no participants reported same-day substance abuse, 
which would have led to censoring of data. The date of HIV 
transmission was approximated as 14 days before the onset of 
seroconversion symptoms, when present [27]; otherwise, it was 
approximated as midway between the dates of the last negative 
and first positive result of an enzyme immunoassay [28]. HIV-
uninfected volunteers were recruited from the San Francisco 
community and had no history of neurological conditions or 
active systemic diseases.
Ethics
The study protocol was approved by the institutional review 
board of each institution involved. All study participants gave 
written consent.
Data Collection and Laboratory Analysis
CSF and blood specimens were obtained and neuropsycholog-
ical testing and MRS were performed at each visit as previously 
described [23, 29]. Study visits were scheduled at baseline, 6 
weeks, and every 6 months thereafter, although there was par-
ticipant variation in the timing and duration of follow-up.
CSF neurofilament light chain (NFL) levels were measured 
with the NF-light enzyme-linked immunosorbent assay kit 
(UmanDiagnostics, Umeå, Sweden), a sensitive immunoassay 
[21], with reference values for the upper limit of normal (ULN) 
of 380  ng/L (for individuals aged 18–29  years), 560  ng/L (for 
those aged 30–39 years), 890 ng/L (for those aged 40–59 years), 
and 1850 ng/L (for those aged >59 years) [21]. CSF and plasma 
albumin levels were measured by nephelometry (Behring 
Nephelometer Analyzer; Behringwerke, Marburg, Germany). 
QAlb was calculated as the ratio of the CSF level of albumin, in 
milligrams/liter, to the plasma level of albumin, in grams/liter 
[22]. Upper limits of normal were based on previously established 
values of <6.8 for ages <45 years and <10.2 for ages >45 years [30]. 
CSF WBCs, lymphocytes, total protein, and HIV RNA were mea-
sured as previously described [9]. Viral loads of <50 copies/mL 
were assigned a value of 49 copies/mL (1.69 on log10 scale).
Neuropsychological performance was determined through 
the appraisal of gross and fine motor skills, processing speed, 
executive function, learning, and verbal memory, using a bat-
tery of 11 tests. Performance was summarized as an aggregate 
total z score and a brief NPZ-4 score (including grooved peg-
board, digit symbol, finger tapping, and timed gait).
Brain magnetic resonance imaging (MRI)/MRS were per-
formed at the San Francisco site only. MRS data were processed 
and analyzed with the spectral fitting software siTools, which 
uses a parametric model of known (metabolites) and modeled 
(macromolecules) spectral components to fit all resonances and 
nonparametric parameters to the baseline value. Metabolite dis-
turbances can indicate neuropathology, including inflammation 
and injury. The ratio of the peak area under the curve for the 
metabolite N-acetylaspartate to the peak area under the curve for 
creatine-containing metabolites (NAA:Cr) is a putative marker 
of neuronal viability and number. We focused spectral acquisi-
tion on the parietal gray matter, as we have previously identified 
metabolite abnormalities in this region during PHI [17, 23].
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Statistical Analysis
Baseline characteristics were summarized as frequencies for 
categorical variables and median values and interquartile 
ranges for continuous variables. Nonparametric, χ2, and Fisher 
exact tests were used for group comparisons. The mixed-ef-
fects model was used to analyze longitudinal change of QAlb 
after transmission. This model includes both fixed and ran-
dom effects in the same analysis, allowing for variation in the 
number and interval of participant follow-up visits. Baseline 
age was included as a fixed-effect covariate in the model. To 
account for a possible nonlinear trajectory of QAlb over time, 
a quadratic term (t2) was included as a fixed-effect covariate. 
The model included a personal intercept for each participant 
as a random effect, allowing the baseline QAlb to vary for each 
participant. As log-transformed results were comparable to 
non–log-transformed analysis, the latter results are reported. 
The plot of fitted group mean QAlb trend was superposed on 
observed individual data. Between-subject and within-sub-
ject correlation were evaluated using the Bland and Altman 
method [31, 32].
Statistical analyses were performed using the SPSS 23.0 sta-
tistical package (IBM, Armonk, NY). The significance level was 
set as a P value of < .05 (2 sided).
RESULTS
Study Participant Characteristics
A total of 106 participants with PHI fulfilled the inclusion 
criteria and had available QAlb values. Nine participants 
experienced clinically overt neurological disorders during 
seroconversion: there were 2 cases of meningitis, 5 of head-
ache with photophobia, 2 of brachial neuritis, and 1 each of 
Guillain-Barre syndrome, facial palsy, and encephalitis. Total 
visits ranged from 1 to 13, with a median of 2, and the max-
imum follow-up duration was 3572  days, with a median of 
50 days. The majority of participants were infected with HIV 
subtype B [9].
The baseline characteristics of participants with PHI and 
uninfected controls are presented in Table 1. The median dura-
tion of HIV infection in participants with PHI was 91  days; 
the plasma viral load during PHI was 1.8 log10 greater relative 
to that in the CSF compartment. As compared to the HIV-
uninfected participants, the PHI cohort had a higher percent-
age of males and was younger. As expected, participants with 
PHI had a lower CD4+ T-cell count, an elevated CD8+ T-cell 
count, and a decreased ratio of CD4+ T cells to CD8+ T cells. 
As previously reported, CSF white blood cell counts were ele-
vated in the PHI group, as well as CSF levels of neopterin, a 
marker of macrophage activation. Despite the younger age, 
participants with PHI had levels of NFL and equivalent CSF 
total protein—2 parameters that increase in level with normal 
aging—that were greater than those for the uninfected group, 
[21, 33, 34].
BBB Permeability at Baseline
At baseline, the mean age-adjusted QAlb was elevated in the 
PHI cohort (5.9; 95% confidence interval [CI], 5.5–6.3) as 
Table 1. Baseline Demographic and Clinical Characteristics of Study Participants, by Human Immunodeficiency Virus (HIV) Status
Characteristic
Primary HIV Infection
(n = 106)
No HIV Infection 
(n = 64) P
Male sex, % (no.) 94 (100) 82 (52) .001
Age, y 36 (29–46) 43 (34–50) .003
Study site
San Francisco, CA 82 64
Gothenburg, Sweden 24 0
Time after HIV transmission, d 91 (53–149) …
CD4+ T-cell count, cells/μL 567 (402–709) 808 (678–1009) <.001
CD8+ T-cell count, cells/μL 954 (714–1358) 487 (343–733) <.001
CD4+ to CD8+ T-cell ratio 0.528 (0.391–0.791) 1.76 (1.32–2.18) <.001
HIV RNA load, log10 copies/mL
In plasma, log10 copies/mL 4.69 (4.08–5.34) …
In CSF, log10 copies/mL 2.83 (2.14–3.51) …
Plasma to CSF ratio 1.81 (1.33–2.28) …
CSF WBC count, cells/mm3 6 (2–11) 2 (0–3) <.001
CSF total protein level, mg/dL 41 (31–51) 41 (31–54) .611
NFL level, pg/mL 518 (391–819) 411 (320–550) <.001
CSF neopterin level, nmol/L 9.6 (6.8–20.4) 5.0 (4.1–6.8) <.001
Neurosymptomatic ARS, % (no.) 8.5 (9) …
Study visits, no. 2 (1–3) …
Follow-up duration, d 50 (0–450) …
Data are median value (interquartile range), unless otherwise indicated.
Abbreviations: ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white blood cell.
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compared to that for controls (5.0; 95% CI, 4.4–5.6; P =  .02). 
On the basis of previously published reference values [30], the 
baseline QAlb was above the age-specific ULN in 22 participants 
with PHI (21%), hereafter referred to as the “high baseline QAlb 
subgroup.” The remaining 84 participants with PHI with base-
line QAlb values below the ULN are referred to hereafter as the 
“normal baseline QAlb subgroup.” The baseline clinical charac-
teristics of these 2 subgroups are summarized in Table 2. Four 
of seventeen participants (24%) in the high baseline QAlb sub-
group had neurosymptomatic seroconversion, compared with 
8 of 64 (13%) in the normal baseline QAlb subgroup, although 
the difference was statistically insignificant. An elevated NFL 
level, CSF total protein level, CSF neopterin (but not blood 
neopterin) level, and CD8+ T-cell count and a decreased ratio 
of plasma to CSF levels of HIV RNA were found in the high 
baseline QAlb subgroup as compared to the normal baseline 
QAlb subgroup.
Longitudinal BBB Permeability in PHI Before cART Initiation
The individual QAlb trajectories for all participants in the PHI 
group over the duration of the study before cART initiation 
are plotted in Figure  1. A  mixed-model analysis to evaluate 
the natural history of BBB integrity in the overall PHI group 
before cART initiation did not reveal a significant change in 
QAlb over time (–0.000436/day; P  =  .092). Figure  2 compares 
the trajectories of the high and normal baseline QAlb groups. 
The high baseline QAlb subgroup showed a declining trend 
(–0.00305/day; P  =  .011), while the QAlb in the normal base-
line QAlb subgroup initially increased (0.00144/day; P  =  .006) 
Table 2. Baseline Clinical Characteristics of Participants With Primary Human Immunodeficiency Virus (HIV) Infection, by Baseline Cerebrospinal Fluid 
(CSF) to Serum Albumin Concentration Quotient (QAlb) Subgroup
Characteristic
High Baseline QAlb
(n = 22)
Normal Baseline QAlb
(n = 84) Pa
Age, y 36 (29–45) 37 (28–46) .797
Time after HIV transmission, d 85 (60–125) 92 (51–150) .785
CD4+ T-cell count, cells/μL 596 (484–681) 550 (389–730) .469
CD8+ T-cell count, cells/μL 1294 (792–1620) 915 (706–1200) .023
CD4+ to CD8+ T-cell ratio 0.463 (0.321–0.791) 0.530 (0.391–0.803) .376
HIV RNA load, log10 copies/mL
In plasma, log10 copies/mL 4.60 (3.91–5.39) 4.69 (4.09–5.32) .629
In CSF, log10 copies/mL 3.23 (1.77–3.87) 2.73 (2.14–3.43) .340
Plasma to CSF ratio 1.27 (0.464–2.16) 1.84 (1.50–2.29) .020
CSF WBC count, cells/mm3 7 (4–13) 5 (2–11) .087
CSF total protein level, mg/dL 59 (52–74) 37 (28–42) <.001
NFL level, pg/mL 857 (468–1474) 498 (360–729) .008
Neopterin level, nmol/L
In blood 18.0 (10.8–28.9) 14 (9.4–21.3) .183
In CSF 14.3 (8.4–32.0) 9.0 (6.5–17.4) .035
Baseline QAlb 9.18 (7.5–11.3) 4.66 (3.57–5.75) <.001
Neurosymptomatic ARS, % (no.) 24 (4) 13 (8) .169b
Study visits, no. 2 (1–3) 2 (1–3) .617
Follow-up duration, d 48 (0–398) 51 (0–455) .715
Data are median value (interquartile range), unless otherwise indicated.
Abbreviations: ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; NFL, neurofilament light chain; WBC, white blood cell.
aValues <.05 were considered statistically significant.
bComparison involved 17 participants in the high baseline QAlb subgroup and 64 in the normal baseline QAlb subgroup and was performed using the Fisher exact test.
Figure  1. Natural history of blood-brain barrier integrity before combination 
antiretroviral therapy in the total cohort. QAlb, cerebrospinal fluid to serum albumin 
concentration quotient.
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and reached a plateau quickly (quadratic time effect P = .004). 
These results indicated the heterogeneous time effect in the 2 
subgroups.
Correlation of BBB Integrity With Markers of Neuropathogenesis
To further evaluate the implications of elevated QAlb, correla-
tions between QAlb and markers of neuronal health were evalu-
ated in pre-cART study intervals (Figure 3). Partial correlation 
coefficients were calculated to correct for the confounding 
effects of age, as the QAlb and NFL level both directly correlate 
with age. The QAlb demonstrated a strong positive correlation 
with the NFL level, a marker of active neuronal injury, upon 
cross-sectional analysis at baseline (r  =  0.497; P  <  .001) and 
longitudinally, with both between-participant (r  =  0.555; 
P < .001) and within-participant (r = 0.523; P = .001) analysis. 
QAlb inversely correlated with NAA:Cr, a cerebral metabolite 
biomarker of neuronal health, upon cross-sectional analy-
sis at baseline (r = –0.352; P =  .015) and longitudinally, with 
between-participant analysis (r  =  –0.387; P  =  .008) but not 
within-participant analysis (r = 0.218; P = .125). MRS was per-
formed at a median interval of 114  days after infection. QAlb 
did not correlate with composite z scores (total z or NPZ4) of 
neuropsychological testing at baseline or in longitudinal anal-
ysis (data not shown).
Characteristics of cART Recipients
Fifty-eight participants with PHI initiated a cART regimen 
during study follow-up, although 1 participant was excluded 
because of virologic failure (defined as 2 consecutive plasma 
samples with an HIV RNA load of >50 copies/mL after 
6 months of ART). Treatment regimens were heterogeneous, 
consisting of 10 integrase-based, 25 protease-based, and 22 
nonnucleoside reverse transcriptase inhibitor–based regimens 
with 19 distinct combinations. cART was initiated at a median 
interval of 225  days after infection, with a median duration 
of follow-up during cART of 402 days. Table 3 compares the 
cross-sectional laboratory parameters before (ie, during the 
last visit before treatment initiation) and after (ie, during 
the last visit of the study) cART initiation in those who initi-
ated cART. There was improvement in most parameters after 
approximately a year of cART, with suppression of plasma 
and CSF HIV RNA levels to the lower limit of detection by 
polymerase chain reaction (P <  .001), increased CD4+ T-cell 
counts (P  <  .001), decreased WBC counts (P  <  .001), and 
decreased blood and CSF neopterin levels (P <  .001). In this 
comparison, the NFL level and albumin ratio did not signifi-
cantly change with cART (640 vs 670 ng/L [P = .911] and 5.18 
vs 5.09 [P = .851], respectively).
Longitudinal History of BBB Integrity Following cART Initiation
A mixed-model analysis was performed to assess the longi-
tudinal trajectory of QAlb over 13 months of cART (Figure 4). 
Three participants were recruited into the cohort after already 
having initiated cART (for 29, 27, and 19 days) and thus were 
included in the linear mixed model (n = 60) but are excluded 
from the group described in Table 3. As cART was initiated at 
a median interval of 225 days after infection (t = 0 in Figure 4), 
this time point corresponded with the linear portion shown in 
Figure 2, in which the quadratic changes of the normal baseline 
subgroup are resolving and reaching a set point. Thus, the initial 
analysis was performed with the total group of cART recipients, 
Figure 2. Natural history of blood-brain barrier integrity before combination antiretroviral therapy (cART) upon cohort stratification. Graphs demonstrate individual partic-
ipant and overall trajectory of the cerebrospinal fluid to serum albumin concentration quotient (QAlb) in cART-naive participants upon stratification into high and low baseline 
QAlb subgroups. Dashed gray lines indicate the upper limits of normal for participants aged <45 years (QAlb, 6.5) and those aged >45 years (QAlb, 10.2).
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rather than separating cART recipients into the high and nor-
mal baseline QAlb subgroups. There was no significant change 
detected in QAlb over the median duration (ie, >1 year) of cART 
(slope, −0.00369/month; P = .174). With group stratification, the 
high baseline QAlb subgroup (n = 7) demonstrated no significant 
change in QAlb over time (P = .783). The low baseline subgroup 
(n = 53) demonstrated a slope of effectively 0 (slope, 0.00008/
month; P = .004), similar to the pre-cART plateau.
DISCUSSION
In this study, we analyzed the natural history of BBB perme-
ability and the influence of early cART during primary HIV 
infection. We show that albumin ratio is mildly elevated in par-
ticipants with PHI, compared with that for uninfected controls, 
when correcting for age. This correction is relevant given that 
BBB permeability increases with normal aging [35] and may 
explain why previous studies have not reported abnormalities 
in BBB permeability during PHI when compared to controls, 
given that most studies of PHI enroll young patients. That 
being said, we have previously identified moderate elevation of 
the albumin ratio during PHI [9, 36] and in participants with 
chronic HIV infection who are cART naive and neuroasymp-
tomatic [9]. Similarly, Li et al have reported a strong associa-
tion between matrix metalloproteinases—enzymatic surrogate 
markers of BBB permeability—and neurocognitive status in 
PHI [37].
The novelty of this study is our finding that BBB perme-
ability undergoes dynamic changes during PHI, even within 
days of transmission. Two distinct trajectories were noted for 
the PHI cohort when analysis was stratified by baseline albu-
min ratio. Those with a normal baseline albumin ratio (ie, a 
ratio below the ULN) showed a mild initial increase that pla-
teaued within the first 1000 days of infection. Despite the ini-
tial rise, the QAlb remained well below the ULN. As will be 
discussed below, it may be that there is an element of subclin-
ical injury associated with this mild rise. The subgroup with a 
Figure 3. Correlation of blood-brain barrier permeability with clinical and laboratory indicators of neuropathogenesis. Abbreviations: Cr, peak area under the creatinine 
concentration curve; NAA, peak area under the N-acetylaspartate concentration curve; NFL, neurofilament light chain level; QAlb, cerebrospinal fluid to serum albumin con-
centration quotient.
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high baseline albumin ratio demonstrated a marked decline 
in the albumin ratio within the first 1000  days of infection. 
Presumably an early rise in albumin ratio occurred immedi-
ately following infection, before participant recruitment, and 
began to resolve during the follow up. Notably, the subgroup 
with a higher baseline albumin ratio was characterized by a 
higher percentage of neurosymptomatic seroconversion, ele-
vated levels of CSF markers of axonal injury and immune acti-
vation, and a higher ratio of CSF to plasma levels of HIV RNA. 
These findings suggest that a subgroup of participants with 
PHI is susceptible to marked BBB disruption, which persists 
even beyond 1000 days after infection, and is associated with 
signs of increased CNS involvement. Factors that predispose 
individuals to one trajectory versus the other warrant further 
investigation.
Previous studies have expounded on the association of 
the albumin ratio with biomarkers of CNS inflammation 
and injury [20]. We confirm that, during PHI, the albumin 
ratio correlates strongly with the level of the axonal injury 
marker, NFL [23], and are the first to demonstrate that it 
inversely correlates with the metabolic marker of neuronal 
health, NAA:Cr. NFL is a sensitive marker of active neuronal 
damage, and its levels correlate with the severity of this dam-
age [38–40]. We have previously shown NFL to be the most 
sensitive neuronal biomarker for assessing HIV neurodegen-
eration, as it can detect subclinical injury in neuroasymp-
tomatic individuals, even during PHI [36, 41]. As disease 
progresses, it is also associated with overt clinical neurolog-
ical disease, thus reflecting not only structural changes, but 
also functional changes [38]. Although NFL is not specific 
for HIV neurodegeneration [36, 39], comorbid neurologi-
cal conditions were excluded from the study onset. Similar 
to QAlb, the NFL level was elevated during PHI, although it 
was below the ULN (<560 ng/L), possibly indicating subclin-
ical damage, which may explain the lack of correlation with 
NPZ-4 test results. In line with this conclusion, we have pre-
viously shown a lack of correlation between NFL levels and 
NPZ-4 results during PHI, despite showing moderate eleva-
tions when compared to findings for uninfected controls [23, 
36]. Similar to the utility of the NFL level as a biomarker 
of early subclinical injury, MRS has been shown to detect 
early HIV-associated neuropathogenesis before detection of 
conventional MRI changes [42]. In a recent study, subjects 
with chronic HIV infection who have cognitive deficits were 
shown to have reduced glutamate and NAA levels in several 
brain regions, most pronounced in the parietal gray matter 
[43]. Here, we extend that finding to PHI.
Once we demonstrated that BBB permeability was altered 
in PHI and associated with markers of neuronal pathology, we 
Table  3. Characteristics of Participants with Primary Human 
Immunodeficiency Virus (HIV) Infection Before and After Initiating 
Combination Antiretroviral Therapy (cART)
Characteristic Before Initiation (n = 57)
After Initiation   
(n = 57) Pa
Age, y 41 (29–46) …
Time after HIV 
transmission, d
225 (96–760) …
Time before ART 
initiation, d
19 (3–85) …
Follow-up visits, no. … 2 (1–6)
cART duration, d … 402 (192–1060)
CD4+ T-cell count, 
cells/μL
431 (282–588) 643 (483–787) <.001
HIV RNA load, log10 copies/mL
In plasma, log10 4.9 (4.4–5.3) 1.69 (1.69–1.69) <.001
In CSF, log10 3.4 (2.6–4.0) 1.69 (1.69–1.69) <.001
Plasma to CSF 
ratio
1.49 (0.71–2.08) 0.00 (0.00–0.20) <.001
CSF WBC count, 
cells/mm3
4 (6–14) 2 (1–3) <.001
CSF total protein 
level, mg/dL
40 (33–50) 35 (29–42) .001b
NFL level, pg/mL 640 (515–965) 670 (453–1072) .911c
QAlb 5.18 (3.92–6.40) 5.09 (3.87–6.21) .832
Neopterin level, 
nmol/L
In blood 18.4 (8.4–24.9) 7.6 (5.2–12.9) <.001
In CSF 13.9 (7.8–21.6) 5.2 (4.7–7.7) <.001
Data are median value (interquartile range). Data before cART initiation were obtained 
during the last visit before treatment initiation, and data after cART initiation were obtained 
during the last visit of the study.
Abbreviations: CSF, cerebrospinal fluid; NFL, neurofilament light chain; QAlb, cerebrospinal 
fluid to serum albumin concentration quotient; WBC, white blood cell.
aGroup comparisons were performed using nonparametric analysis for related samples. 
Values <.05 were considered statistically significant.
bComparison is for 21 paired values.
cComparison is for 42 paired values.
Figure 4. Effects of combination antiretroviral therapy (cART) on the trajectory of 
blood-brain barrier permeability. Scatterplot shows individual participant trajecto-
ries and overall cohort trajectories of the cerebrospinal fluid to serum albumin con-
centration quotient (QAlb) before and after cART initiation (indicated by the dashed 
line at t = 0). Linear mixed model analysis generated the two slopes. Months before 
cART initiation are negative values.
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assessed whether early cART could remediate these changes. 
Surprisingly, the effect of cART on BBB permeability has not 
been intensely evaluated. In an unpublished study, Crozier et al 
observed the gradual diminishment of the median albumin 
ratio (from 6.48 to 6.09) in 16 neuroasymptomatic participants 
with chronic HIV infection after 200 days of cART [44]; thus, 
although BBB integrity improved over time with cART, a return 
to baseline or near baseline function may take years. In contrast, 
Abdulle et al reported no significant reduction in BBB perme-
ability after 2 years of cART in 38 neuroasymptomatic partic-
ipants [45]. Importantly, the median baseline albumin ratio 
among participants in the study by Crozier et  al was greater 
than that of participants in the study by Abdulle et al (6.48 vs 
4.45), potentially contributing to the discrepancy in the cohort 
response to cART.
In our study, cART, initiated at a median interval of 225 days 
after infection, was effective in suppressing CSF and plasma 
HIV RNA, suggesting medication compliance and effective-
ness. Notably, the inflammatory marker neopterin improved to 
the upper level of normal limits both in the plasma and CSF. 
Despite this systemic (including CNS) suppression of viral rep-
lication and inflammation, the NFL level and albumin ratio 
were unchanged. The pre-cART measurement of the albumin 
ratio was comparable to that of the age-matched uninfected 
controls and thus may indicate that the acute changes of the 
albumin ratio in the high baseline QAlb subgroup had largely 
resolved and reached a level near baseline once cART was ini-
tiated at a median interval of 225 days after infection. On the 
other hand, although the NFL level was below the age-specific 
ULN (<840 pg/mL), it was significantly elevated as compared to 
that for uninfected controls and the baseline PHI cohort, given 
only a marginal age difference. There is a gradual normalization 
of the NFL level following axonal injury, which is unlikely to 
persist for over a year [46]. Thus, this persistently elevated level 
of NFL may reflect continued subclinical injury despite cART 
and what appears to be a largely normal albumin ratio.
We hypothesize that perhaps (1) the initially altered BBB per-
meability initiated CNS injury, which persists despite resolution 
of BBB integrity; (2) the mechanism of injury is independent of 
BBB integrity; or (3) BBB permeability is mildly elevated and 
has not fully returned to baseline, resulting in persisting neuro-
nal injury. Alternatively, it is possible that, despite the large sam-
ple size, we still have insufficient power to detect a significant 
change in the NFL level and QAlb after cART initiation. Further 
studies are necessary to elucidate the possible explanation. 
Notably, a previous study showed normalization of the ratio of 
CD4+ to CD8+ T cells during PHI only when cART was initi-
ated within 6 months after transmission [47]. Furthermore, in a 
cohort of individuals who started treatment during acute HIV 
infection, the CSF NFL level was not elevated at baseline nor 
after 6 and 24 months of cART [48]. The effects of earlier cART 
intervention on normalization of the albumin ratio should be 
investigated.
This study has several limitations. QAlb is affected by many 
factors not accounted for in this study, including body weight 
and smoking [35]. Although cholesterol and other cardio-
vascular risk factors were not routinely screened, none of the 
participants had a known history of clinically apparent cardio-
vascular disease, such as coronary artery disease, peripheral 
vascular disease, or stroke. One participant, in the low baseline 
group, had a known diagnosis of diabetes mellitus type 2. Abuse 
of substances such as cocaine has been shown to at least tran-
siently increase BBB permeability [49]; thus, misreporting of 
ongoing drug use or long-term effects of previous drug use can-
not be discounted as confounding factors. Furthermore, given 
the observational nature of this study, cART regimens were het-
erogeneous, which may result in distinct effects on the BBB.
BBB permeability undergoes a dynamic process during PHI, 
demonstrating acute changes within days. We identified 2 sub-
groups of participants with PHI with different albumin ratio 
trajectories: one with a presumed acute increase and gradual 
improvement over the course of infection and a second with a 
mild initial increase. BBB permeability correlated with mark-
ers of neuropathogenesis. Initiation of cART in the first year 
of infection did not significantly alter BBB permeability in our 
study. Further investigations should test the effects of earlier 
cART initiation, especially in individuals with signs of early 
BBB disruption.
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